EnGeneIC Ltd Selected as Winner in Drug Delivery Technology category by Fierce Innovation Awards – LifeSciences Edition 2019

EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, announced that it is the winner in this year’s Drug Delivery Technology category given by Fierce Innovation Awards – LifeSciences Edition, which is a peer-reviewed awards program from the publisher of FierceBiotech and FiercePharma.

EnGeneIC’s EDV™ is a globally unique cyto-immunotherapy that is able to directly kill cancer cells as well as provoking a potent anti-tumor immune response with little to no toxicity, even in late stage drug-resistant cancers.